Novartis’ new injectable psoriasis drug Cosentyx was shown to act rapidly on psoriatic arthritis. Swiss drug maker Novartis believes that its new injectable drug Cosentyx could surpass annual sales forecasts as new clinical data have shown the drug’s long term benefits as treatment for psoriatic arthritis. The drug company has already shown the two year benefits of its drug in psoriasis as well as its one-year effect on another long-term inflammatory disease known as ankylosing spondylitis. While biologics have been used to treat disease for more than 100 years, modern-day techniques have made biologics much more widely available as treatments in the last decade. Screening for tuberculosis (TB) or other infectious diseases is required before starting treatment with Cosentyx, Enbrel, Humira, Remicade, Simponi and Stelara. Anyone considering taking a biologic drug should talk with his or her doctor about the short- and long-term side effects and risks. Call your doctor if you are experiencing any side effects with biologic drugs. Cosentyx is the first and only FDA-approved psoriasis treatment that binds specifically to IL-17A, which is involved in inflammatory and immune response, and inhibits interaction with the IL-17A receptor. Additionally, patients with psoriasis are at increased risk for other chronic illnesses.
Sixty-five percent of psoriasis patients taking Cosentyx had completely or almost completely clear skin after three months. In four clinical trials with a total of 2,403 patients taking either Cosentyx or a placebo, more than 80 percent of patients taking Cosentyx saw 75 percent or more of their symptoms disappear. This is the best data we have for any drug for long-term therapy of this chronic disease. Marketed by Novartis, the drug will compete against other systemic therapies, such as AbbVie’s Humira (adalimumab) and Amgen’s Enbrel (etanercept). Novartis is increasingly confident about the potential of its new injectable drug Cosentyx, as fresh clinical data confirms its long-term benefits in treating psoriatic arthritis. Cosentyx was approved by the U.S. Food and Drug Administration in January for treating the painful skin condition plaque psoriasis, but the company also has high hopes for the product in related conditions. Novartis had already shown two-year benefits from Cosentyx in psoriasis and one-year effects in ankylosing spondylitis, another long-term inflammatory disease. Durable long-term responses with ixekizumab, secukinumab.
Aetna considers ustekinumab experimental and investigational for all other indications, including Crohn’s disease, erythrodermic psoriasis, multiple sclerosis, pyoderma gangrenosum, and spondyloarthropathy because its effectiveness for these indications has not been established. More than 2 treatments of alefacept are considered experimental and investigational. Lesions appear on any part of the skin, but particularly the scalp, sacral area, and over the extensor aspect of the knees and elbows. The authors stated that efalizumab has emerged as an important addition to the dermatological pharmacopeia for the long-term treatment of psoriasis. Despite advances in psoriasis care, effective long-term treatment of psoriasis remains a challenge to both patients and physicians. The risk attributable of TNF-alpha and other biological therapies may be outweighed by the beneficial consequences of treating the psoriasis, depending on disease severity. The safety profile of Cosentyx was comparable to Stelara and consistent with previously reported phase III clinical trials for Cosentyx. Studies still haven’t demonstrated whether long-term use of secukinumab or other biologics has a positive benefit on cardiovascular function, over time. As with any new therapy, additional long-term safety studies are needed.
Fda Approves New Psoriasis Drug That Promises Huge Skin Improvement
Helping psoriasis sufferers achieve clear skin remains the goal for both patients and their physicians, yet many patients still do not achieve this, said Christi Shaw, US Country Head, President of Novartis Corporation and Novartis Pharmaceuticals Corporation. Additionally, patients with psoriasis are at increased risk for other chronic illnesses. CONTRAINDICATIONSCOSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients. The ultimate aim of psoriasis treatment is clear skin, and the Psoriasis Area Severity Index (PASI) 90 response is considered an important measure of treatment success2,3. CLEAR (Comparison to assess Long-term Efficacy, sAfety and toleRability of secukinumab vs. Includes: indications, dosage, adverse reactions, pharmacology and more. For other psoriatic arthritis patients, administer Cosentyx with or without a loading dosage by subcutaneous injection. One case of exacerbation of Crohn’s disease was reported from long-term non-controlled portions of ongoing clinical trials in plaque psoriasis see Warnings and Precautions (5. Overall there is no real difference (performance) between drugs long term. Insurance would love you on Humira so they can give you biosh errr mean biosimilar as soon as possible. Besides you would not have to worry about biosimilars for a few years. There are others on this forum who more than likely reconmend Stelara. The ultimate aim of psoriasis treatment is clear skin, and the PASI 90 response is considered an important measure of treatment success. Cosentyx is approved by the FDA for moderate to severe plaque psoriasis in adults.